<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02459262</url>
  </required_header>
  <id_info>
    <org_study_id>2014-004542-10</org_study_id>
    <nct_id>NCT02459262</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.</brief_title>
  <acronym>MVX13211</acronym>
  <official_title>A Two-part, Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of a Dose Range og Group B Streptococcus Vaccine in Healthy Female Volunteers Aged 18 to 40.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minervax ApS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minervax ApS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part A: The primary objective is to evaluate the safety and tolerability of a potential&#xD;
      vaccine against Group B streptococcus.&#xD;
&#xD;
      Part B: To evaluate the long term safety profile of the GBS-NN vaccine up to one year&#xD;
      following the first dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A: Subjects will receive 2 doses of the vaccine, GBS-NN, and will be followed for 12&#xD;
      weeks after the first dose of the vaccine. The following safety endpoints will be evaluated&#xD;
      to support this objective: local and systemic reactogenicity; adverse events; laboratory&#xD;
      tests; urinalysis; vital signs; 12-Lead ECG parameters; physical examination. In addition&#xD;
      hereto, immunological parameters will be evaluated.&#xD;
&#xD;
      Part B: Subjects will receive one or 2 doses of GBS-NN, and will be followed for 12 months&#xD;
      after the first dose of the vaccine. The following safety endpoints will be evaluated to&#xD;
      support this objective: local and systemic reactogenicity; adverse events; laboratory tests;&#xD;
      urinalysis; vital signs; 12-Lead ECG parameters; physical examination. In addition hereto,&#xD;
      immunological parameters will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">April 21, 2017</completion_date>
  <primary_completion_date type="Actual">April 12, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A Number of Participants With Treatment Emergent Adverse Events</measure>
    <time_frame>12 weeks (to Day 85)</time_frame>
    <description>Number of Participants with Treatment Emergent Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B Number of Participants With Treatment Emergent Adverse Events</measure>
    <time_frame>12 weeks (to Day 85)</time_frame>
    <description>Number of Participants with Treatment Emergent Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A Antibody Concentration</measure>
    <time_frame>12 weeks (Day 85)</time_frame>
    <description>Geometric mean antibody concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B Antibody Concentration</measure>
    <time_frame>12 weeks (Day 85)</time_frame>
    <description>Geometric mean antibody concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B Antibody Concentration</measure>
    <time_frame>1 year (Day 365)</time_frame>
    <description>Geometric mean antibody concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B Number of Participants With Treatment Emergent Adverse Events</measure>
    <time_frame>Day 85 to Day 365</time_frame>
    <description>Number of Participants with Treatment Emergent Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Infection by Streptococcus Group B</condition>
  <arm_group>
    <arm_group_label>GBS-NN Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GBS-NN vaccine administered either adsorbed to Alhydrogel® or alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile dilution buffer with Alhydrogel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo will contain either Alhydrogel® or buffer alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GBS-NN vaccine</intervention_name>
    <description>Three dose levels will be administered, with and without Alhydrogel®</description>
    <arm_group_label>GBS-NN Vaccine</arm_group_label>
    <arm_group_label>Sterile dilution buffer with Alhydrogel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult female volunteers (as determined by medical history, physical&#xD;
             examination, laboratory test values, vital signs and electrocardiograms [ECGs] at&#xD;
             screening) aged 18 - 40 years.&#xD;
&#xD;
          2. Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2.&#xD;
&#xD;
          3. Volunteers weight ≥ 50kg and ≤100kg at screening.&#xD;
&#xD;
          4. Able to voluntarily provide written informed consent to participate in the study.&#xD;
&#xD;
          5. Must understand the purposes and risks of the study and agree to follow the&#xD;
             restrictions and schedule of procedures as defined in the protocol.&#xD;
&#xD;
          6. Volunteers must be pre-menopausal. Volunteers who have had a hysterectomy will have&#xD;
             pre-menopausal status confirmed by a FSH and oestradiol test.&#xD;
&#xD;
          7. Females of childbearing potential must have a negative pregnancy test at screening (β&#xD;
             HCG) and prior to each dose and must be willing to use an adequate and highly&#xD;
             effective method of contraception until at least Day 85 of the study. A highly&#xD;
             effective method of birth control is defined as one which results in a low failure&#xD;
             rate (i.e. less than 1% per year) when used consistently and correctly such as&#xD;
             sterilisation, implants, injectables, combined oral contraceptives, IUDs (Intrauterine&#xD;
             Device), condoms, occlusive caps (cervical/vault caps) with spermicidal foam/gel/&#xD;
             film/cream/suppository. True sexual abstinence is acceptable when this is in line with&#xD;
             the preferred and usual lifestyle of the volunteer (periodic abstinence e.g. calendar,&#xD;
             ovulation, symptothermal, post-ovulation methods, declaration of abstinence for the&#xD;
             duration of the trial, and withdrawal are not acceptable methods of contraception)&#xD;
&#xD;
          8. In Part A: Volunteers must be non-smokers for at least 3 months prior to first&#xD;
             studyvaccine administration. In Part B: Volunteers may be light smokers i.e. up to a&#xD;
             maximum of 5 cigarettes per day or nicotine equivalent.&#xD;
&#xD;
          9. Must be willing to consent to have data entered into The Over Volunteering Prevention&#xD;
             System (TOPS).&#xD;
&#xD;
         10. The volunteer's primary care physician has confirmed within the last 12 months that&#xD;
             there is nothing in their medical history that would preclude their enrolment into a&#xD;
             clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Volunteers with history or presence of significant cardiovascular disease, pulmonary,&#xD;
             hepatic, gallbladder or biliary tract, renal, haematological, gastrointestinal,&#xD;
             endocrine, immunologic, dermatological, neurological, psychiatric, autoimmune disease&#xD;
             or current infection.&#xD;
&#xD;
          2. Pregnant or lactating females.&#xD;
&#xD;
          3. Laboratory values at screening which are deemed to be clinically significant, unless&#xD;
             agreed in advance by the Sponsor's Responsible Medic and Principal Investigator.&#xD;
&#xD;
          4. Current or history of drug or alcohol abuse, or a positive alcohol breath test prior&#xD;
             to first dosing.&#xD;
&#xD;
          5. Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.&#xD;
&#xD;
          6. Participation in a clinical drug study during the 90 days preceding the initial dose&#xD;
             in this study.&#xD;
&#xD;
          7. Any significant illness during the 4 weeks preceding check-in for this study (Day 1).&#xD;
&#xD;
          8. Volunteers with a history of severe allergic reactions after previous vaccination.&#xD;
&#xD;
          9. Volunteers who have received any vaccine within 30 days of screening, or who are&#xD;
             planning to receive a vaccine up to Day 85 of the study.&#xD;
&#xD;
         10. Volunteers receiving immunosuppressive therapy (e.g. systemic steroids, cancer&#xD;
             therapies, methotrexate, azathioprine) in the 6 months prior to screening, antibiotics&#xD;
             within 10 days of receiving the first dose or taking any short-term medications&#xD;
             including over-the-counter preparations, vitamins, herbal and/or mineral supplements&#xD;
             within 7 days of the first dose. Chronic medications such as antihypertensives,&#xD;
             bronchodilators, oral contraceptives or statins that do not affect the immune system,&#xD;
             will be permitted and allowed to continue during the study at the discretion of the&#xD;
             Investigator. Paracetamol will be permitted for the treatment of headache or other&#xD;
             symptoms.&#xD;
&#xD;
         11. Volunteers with tattoos at the proposed site of vaccine administration.&#xD;
&#xD;
         12. Donation of blood or blood products within 90 days prior to vaccine administration.&#xD;
&#xD;
         13. Volunteers who, in the opinion of the Investigator, are unsuitable for participation&#xD;
             in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Fisher, PM/CEO</last_name>
    <role>Study Director</role>
    <affiliation>MinervaX ApS, Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biokinetic Europ Ltd</name>
      <address>
        <city>Belfast</city>
        <zip>BT2 7BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 22, 2015</study_first_submitted>
  <study_first_submitted_qc>May 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <results_first_submitted>November 30, 2020</results_first_submitted>
  <results_first_submitted_qc>January 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2021</results_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT02459262/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Part A: Healthy females were recruited to receive two doses of either GBS-NN vaccine with or without Alhydrogel® gel adjuvant at three dose levels (10mcg, 50mcg, 250mcg) or placebo.&#xD;
Part B: Doses of 50mcg (2 doses) and 100mcg (1 and 2 doses) were selected from the antibody levels at 8 weeks from Part A and vaccine was administered with Alhydrogel®. Participants were healthy females and did not include participants from Part A. They were followed up for 1 year.</recruitment_details>
      <pre_assignment_details>Part A was the dose-finding part of the study and 60 healthy female participants received either 2 doses of GBS-NN 10mcg, 50mcg, 250mcg or placebo (4:1 ratio of active:placebo). Based on the 8 week (Day 57) antibody levels from Part A, 180 healthy female participants in Part B were recruited to receive either 2 doses of GBS-NN 50mcg, 2 doses of GBS-NN 100mcg, 1 dose of GBS-NN 100mcg or placebo (3:1 ratio of active to placebo). Participants in Part A were not allowed to participate In Part B.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A GBS-NN Vaccine 10mcg</title>
          <description>GBS-NN 10mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="P2">
          <title>Part A GBS-NN Vaccine 50mcg</title>
          <description>GBS-NN 50mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="P3">
          <title>Part A GBS-NN Vaccine 250mcg</title>
          <description>GBS-NN 250mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="P4">
          <title>Part A GBS-NN 10mcg Vaccine Administered With Alhydrogel® Adjuvant</title>
          <description>GBS-NN 10mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="P5">
          <title>Part A GBS-NN 50mcg Vaccine Administered With Alhydrogel® Adjuvant</title>
          <description>GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="P6">
          <title>Part A GBS-NN 250mcg Vaccine Administered With Alhydrogel® Adjuvant</title>
          <description>GBS-NN 250mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="P7">
          <title>Part A Placebo</title>
          <description>Alhydrogel® mixed with dilution buffer or buffer alone administered by intramuscular injection</description>
        </group>
        <group group_id="P8">
          <title>Part B GBS-NN Vaccine 50mcg</title>
          <description>GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="P9">
          <title>Part B GBS-NN Vaccine 100mcg 2 Dose Regimen</title>
          <description>GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="P10">
          <title>Part B GBS-NN Vaccine 100mcg Single Dose</title>
          <description>GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1</description>
        </group>
        <group group_id="P11">
          <title>Part B Placebo</title>
          <description>Alhydrogel® mixed with dilution buffer and administered by intramuscular injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="45"/>
                <participants group_id="P9" count="45"/>
                <participants group_id="P10" count="45"/>
                <participants group_id="P11" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="45"/>
                <participants group_id="P9" count="45"/>
                <participants group_id="P10" count="44"/>
                <participants group_id="P11" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A GBS-NN Vaccine 10mcg</title>
          <description>GBS-NN 10mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="B2">
          <title>Part A GBS-NN Vaccine 50mcg</title>
          <description>GBS-NN 50mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="B3">
          <title>Part A GBS-NN Vaccine 250mcg</title>
          <description>GBS-NN 250mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="B4">
          <title>Part A GBS-NN Vaccine 10mcg With Alhydrogel® Adjuvant</title>
          <description>GBS-NN 10 mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="B5">
          <title>Part A GBS-NN Vaccine 50mcg With Alhydrogel® Adjuvant</title>
          <description>GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="B6">
          <title>Part A GBS-NN Vaccine 250mcg With Alhydrogel® Adjuvant</title>
          <description>GBS-NN 250mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="B7">
          <title>Part A Placebo</title>
          <description>Alhydrogel® mixed with dilution buffer or buffer alone administered by intramuscular injection</description>
        </group>
        <group group_id="B8">
          <title>Part B GBS-NN Vaccine 50mcg</title>
          <description>GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="B9">
          <title>Part B GBS-NN Vacine 100mcg 2 Dose Regimen</title>
          <description>GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="B10">
          <title>Part B GBS-NN Vacine 100mcg Single Dose</title>
          <description>GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1</description>
        </group>
        <group group_id="B11">
          <title>Part B Placebo</title>
          <description>Alhydrogel® mixed with dilution buffer and administered by intramuscular injection</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="45"/>
            <count group_id="B9" value="45"/>
            <count group_id="B10" value="45"/>
            <count group_id="B11" value="45"/>
            <count group_id="B12" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="4.8"/>
                    <measurement group_id="B2" value="29.3" spread="6.6"/>
                    <measurement group_id="B3" value="30.4" spread="5.0"/>
                    <measurement group_id="B4" value="28.3" spread="7.4"/>
                    <measurement group_id="B5" value="31.3" spread="4.5"/>
                    <measurement group_id="B6" value="30.4" spread="5.7"/>
                    <measurement group_id="B7" value="28.5" spread="6.6"/>
                    <measurement group_id="B8" value="29.0" spread="6.3"/>
                    <measurement group_id="B9" value="30.3" spread="6.0"/>
                    <measurement group_id="B10" value="29.4" spread="6.5"/>
                    <measurement group_id="B11" value="28.7" spread="6.5"/>
                    <measurement group_id="B12" value="29.5" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="45"/>
                    <measurement group_id="B9" value="45"/>
                    <measurement group_id="B10" value="45"/>
                    <measurement group_id="B11" value="45"/>
                    <measurement group_id="B12" value="240"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="45"/>
                    <measurement group_id="B9" value="45"/>
                    <measurement group_id="B10" value="45"/>
                    <measurement group_id="B11" value="44"/>
                    <measurement group_id="B12" value="239"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="45"/>
                    <measurement group_id="B9" value="45"/>
                    <measurement group_id="B10" value="45"/>
                    <measurement group_id="B11" value="44"/>
                    <measurement group_id="B12" value="239"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="45"/>
                    <measurement group_id="B9" value="45"/>
                    <measurement group_id="B10" value="45"/>
                    <measurement group_id="B11" value="45"/>
                    <measurement group_id="B12" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part A Number of Participants With Treatment Emergent Adverse Events</title>
        <description>Number of Participants with Treatment Emergent Adverse Events</description>
        <time_frame>12 weeks (to Day 85)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A GBS-NN Vaccine 10mcg</title>
            <description>GBS-NN 10mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O2">
            <title>Part A GBS-NN Vaccine 50mcg</title>
            <description>GBS-NN 50mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O3">
            <title>Part A GBS-NN Vaccine 250mcg</title>
            <description>GBS-NN 250mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O4">
            <title>Part A GBS-NN Vaccine 10mcg With Alhydrogel® Adjuvant</title>
            <description>GBS-NN 10 mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O5">
            <title>Part A GBS-NN Vaccine 50mcg With Alhydrogel® Adjuvant</title>
            <description>GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O6">
            <title>Part A GBS-NN Vaccine 250mcg With Alhydrogel® Adjuvant</title>
            <description>GBS-NN 250mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O7">
            <title>Part A Placebo</title>
            <description>Alhydrogel® mixed with dilution buffer or buffer alone administered by intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Part A Number of Participants With Treatment Emergent Adverse Events</title>
          <description>Number of Participants with Treatment Emergent Adverse Events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B Number of Participants With Treatment Emergent Adverse Events</title>
        <description>Number of Participants with Treatment Emergent Adverse Events</description>
        <time_frame>12 weeks (to Day 85)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part B GBS-NN Vaccine 50mcg</title>
            <description>GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O2">
            <title>Part B GBS-NN Vacine 100mcg 2 Dose Regimen</title>
            <description>GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O3">
            <title>Part B GBS-NN Vacine 100mcg Single Dose</title>
            <description>GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1</description>
          </group>
          <group group_id="O4">
            <title>Part B Placebo</title>
            <description>Alhydrogel® mixed with dilution buffer and administered by intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Part B Number of Participants With Treatment Emergent Adverse Events</title>
          <description>Number of Participants with Treatment Emergent Adverse Events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A Antibody Concentration</title>
        <description>Geometric mean antibody concentration</description>
        <time_frame>12 weeks (Day 85)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A GBS-NN Vaccine 10mcg</title>
            <description>GBS-NN 10mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O2">
            <title>Part A GBS-NN Vaccine 50mcg</title>
            <description>GBS-NN 50mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O3">
            <title>Part A GBS-NN Vaccine 250mcg</title>
            <description>GBS-NN 250mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O4">
            <title>Part A GBS-NN Vaccine 10mcg With Alhydrogel® Adjuvant</title>
            <description>GBS-NN 10 mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O5">
            <title>Part A GBS-NN Vaccine 50mcg With Alhydrogel® Adjuvant</title>
            <description>GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O6">
            <title>Part A GBS-NN Vaccine 250mcg With Alhydrogel® Adjuvant</title>
            <description>GBS-NN 250mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O7">
            <title>Part A Placebo</title>
            <description>Alhydrogel® mixed with dilution buffer or buffer alone administered by intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Part A Antibody Concentration</title>
          <description>Geometric mean antibody concentration</description>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.977" lower_limit="0.021" upper_limit="35.80"/>
                    <measurement group_id="O2" value="2.926" lower_limit="0.27" upper_limit="17.40"/>
                    <measurement group_id="O3" value="7.195" lower_limit="0.865" upper_limit="106"/>
                    <measurement group_id="O4" value="16.864" lower_limit="1.11" upper_limit="263"/>
                    <measurement group_id="O5" value="14.999" lower_limit="2.95" upper_limit="83.00"/>
                    <measurement group_id="O6" value="25.431" lower_limit="0.59" upper_limit="277"/>
                    <measurement group_id="O7" value="0.199" lower_limit="0.03" upper_limit="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>The objectives for Part A were to evaluate the effect of adjuvant and to inform the selection of dose levels for Part B. The study was not powered for inter-group comparisons.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>ANOVA repeated measures: In-transformed antibody concentrations as dependent variable; dose level, time, presence of adjuvant and dose*time interaction as fixed effects; subjects as random effects</non_inferiority_desc>
            <p_value>0.0193</p_value>
            <p_value_desc>Adjuvant effect at Day 85, the primary immunological endpoint</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjuvant effect, with higher antibody concentration values after all dose levels of vaccine was significant at all time points (D29, D43, D57, Day 85)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B Antibody Concentration</title>
        <description>Geometric mean antibody concentration</description>
        <time_frame>12 weeks (Day 85)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part B GBS-NN Vaccine 50mcg</title>
            <description>GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O2">
            <title>Part B GBS-NN Vacine 100mcg 2 Dose Regimen</title>
            <description>GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O3">
            <title>Part B GBS-NN Vacine 100mcg Single Dose</title>
            <description>GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1</description>
          </group>
          <group group_id="O4">
            <title>Part B Placebo</title>
            <description>Alhydrogel® mixed with dilution buffer and administered by intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Part B Antibody Concentration</title>
          <description>Geometric mean antibody concentration</description>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.914" lower_limit="0.90" upper_limit="247.00"/>
                    <measurement group_id="O2" value="15.459" lower_limit="0.35" upper_limit="314.00"/>
                    <measurement group_id="O3" value="3.035" lower_limit="0.17" upper_limit="50.20"/>
                    <measurement group_id="O4" value="0.234" lower_limit="0.03" upper_limit="15.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B Antibody Concentration</title>
        <description>Geometric mean antibody concentration</description>
        <time_frame>1 year (Day 365)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part B GBS-NN Vaccine 50mcg</title>
            <description>GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O2">
            <title>Part B GBS-NN Vacine 100mcg 2 Dose Regimen</title>
            <description>GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O3">
            <title>Part B GBS-NN Vacine 100mcg Single Dose</title>
            <description>GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1</description>
          </group>
          <group group_id="O4">
            <title>Part B Placebo</title>
            <description>Alhydrogel® mixed with dilution buffer and administered by intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Part B Antibody Concentration</title>
          <description>Geometric mean antibody concentration</description>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.201" lower_limit="0.24" upper_limit="58.40"/>
                    <measurement group_id="O2" value="5.934" lower_limit="0.20" upper_limit="314.00"/>
                    <measurement group_id="O3" value="1.596" lower_limit="0.06" upper_limit="117.00"/>
                    <measurement group_id="O4" value="0.263" lower_limit="0.03" upper_limit="50.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B Number of Participants With Treatment Emergent Adverse Events</title>
        <description>Number of Participants with Treatment Emergent Adverse Events</description>
        <time_frame>Day 85 to Day 365</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part B GBS-NN Vaccine 50mcg</title>
            <description>GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O2">
            <title>Part B GBS-NN Vacine 100mcg 2 Dose Regimen</title>
            <description>GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
          </group>
          <group group_id="O3">
            <title>Part B GBS-NN Vacine 100mcg Single Dose</title>
            <description>GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1</description>
          </group>
          <group group_id="O4">
            <title>Part B Placebo</title>
            <description>Alhydrogel® mixed with dilution buffer and administered by intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Part B Number of Participants With Treatment Emergent Adverse Events</title>
          <description>Number of Participants with Treatment Emergent Adverse Events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Part A: to 12 weeks (D85) Part B: to 12 weeks (D85)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part A GBS-NN Vaccine 10mcg</title>
          <description>GBS-NN 10mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="E2">
          <title>Part A GBS-NN Vaccine 50mcg</title>
          <description>GBS-NN 50mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="E3">
          <title>Part A GBS-NN Vaccine 250mcg</title>
          <description>GBS-NN 250mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="E4">
          <title>Part A GBS-NN Vaccine 10mcg With Alhydrogel® Adjuvant</title>
          <description>GBS-NN 10 mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="E5">
          <title>Part A GBS-NN Vaccine 50mcg With Alhydrogel® Adjuvant</title>
          <description>GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="E6">
          <title>Part A GBS-NN Vaccine 250mcg With Alhydrogel® Adjuvant</title>
          <description>GBS-NN 250mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="E7">
          <title>Part A Placebo</title>
          <description>Alhydrogel® mixed with dilution buffer or buffer alone administered by intramuscular injection</description>
        </group>
        <group group_id="E8">
          <title>Part B GBS-NN Vaccine 50mcg</title>
          <description>GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="E9">
          <title>Part B GBS-NN Vacine 100mcg 2 Dose Regimen</title>
          <description>GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29</description>
        </group>
        <group group_id="E10">
          <title>Part B GBS-NN Vacine 100mcg Single Dose</title>
          <description>GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1</description>
        </group>
        <group group_id="E11">
          <title>Part B Placebo</title>
          <description>Alhydrogel® mixed with dilution buffer and administered by intramuscular injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Spontaneous abortion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="41" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="39" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="31" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="37" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="26" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="26" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="16" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="18" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="12" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="11" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Per Fisher DPhil</name_or_title>
      <organization>MinervaX ApS</organization>
      <phone>+45 20 25 20 38</phone>
      <email>pbf@minervax.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

